Cargando…

Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells

Resistance is one limitation of sorafenib in the treatment of hepatocellular carcinoma (HCC). Insulin-like growth factor-1 receptor (IGF-1R) is involved in cancer cell proliferation. To assess the potential synergistic antitumor effects of picropodophyllin (PPP), an IGF-1R inhibitor, HLF and PLC/PRL...

Descripción completa

Detalles Bibliográficos
Autores principales:	TOMIZAWA, MINORU, SHINOZAKI, FUMINOBU, MOTOYOSHI, YASUFUMI, SUGIYAMA, TAKAO, YAMAMOTO, SHIGENORI, SUEISHI, MAKOTO
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186500/ https://www.ncbi.nlm.nih.gov/pubmed/25289088 http://dx.doi.org/10.3892/ol.2014.2484

Ejemplares similares

Short hairpin RNA of frizzled-2 suppresses the proliferation of hepatocellular carcinoma cells
por: TOMIZAWA, MINORU, et al.
Publicado: (2014)

Niclosamide suppresses Hepatoma cell proliferation via the Wnt pathway
por: Tomizawa, Minoru, et al.
Publicado: (2013)

Association between juxtapapillary diverticulum and acute cholangitis determined using laboratory data
por: Tomizawa, Minoru, et al.
Publicado: (2014)

Elevated levels of alanine transaminase and triglycerides within normal limits are associated with fatty liver
por: TOMIZAWA, MINORU, et al.
Publicado: (2014)

Comparison of Laboratory Data of Acute Cholangitis Patients Treated with or without Immunosuppressive Drugs
por: Tomizawa, Minoru, et al.
Publicado: (2014)

Improved Survival and Initiation of Differentiation of Human Induced Pluripotent Stem Cells to Hepatocyte-Like Cells upon Culture in William’s E Medium followed by Hepatocyte Differentiation Inducer Treatment
por: Tomizawa, Minoru, et al.
Publicado: (2016)

Signal Intensity of Superb Microvascular Imaging Correlates with the Severity of Acute Cholecystitis
por: Tomizawa, Minoru, et al.
Publicado: (2016)

Duodenal Adenocarcinoma Diagnosed from a Biopsy Specimen of a Depressed Lesion Obtained by Magnifying Endoscopy
por: Tomizawa, Minoru, et al.
Publicado: (2016)

A Case of Gastrointestinal Stromal Tumor That Underwent Endoscopic Ultrasound-Guided Aspiration with a 25-Gauge Biopsy Needle
por: Tomizawa, Minoru, et al.
Publicado: (2016)

Survival of Primary Human Hepatocytes and Death of Induced Pluripotent Stem Cells in Media Lacking Glucose and Arginine
por: Tomizawa, Minoru, et al.
Publicado: (2013)

Frizzled-2: A potential novel target for molecular pancreatic cancer therapy
por: TOMIZAWA, MINORU, et al.
Publicado: (2014)

Correction: Survival of Primary Human Hepatocytes and Death of Induced Pluripotent Stem Cells in Media Lacking Glucose and Arginine
por: Tomizawa, Minoru, et al.
Publicado: (2014)

Diffusion-weighted imaging and diffusion-weighted whole-body imaging with background body signal suppression for characterizing esophageal cancer: a case report
por: Tomizawa, Minoru, et al.
Publicado: (2013)

Molecular Characterization of Acquired Tolerance of Tumor Cells to Picropodophyllin (PPP)
por: Hashemi, Jamileh, et al.
Publicado: (2011)

Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: Clinical implications
por: FENG, XIAOYING, et al.
Publicado: (2011)

Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivo
por: Tarnowski, Maciej, et al.
Publicado: (2017)

The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma
por: Wang, Mingda, et al.
Publicado: (2019)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic
por: Bieghs, Liesbeth, et al.
Publicado: (2014)

Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells
por: Moon, Byul, et al.
Publicado: (2022)

Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma
por: Jiang, Xiufeng, et al.
Publicado: (2015)

Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells
por: Liu, Jianhua, et al.
Publicado: (2017)

The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin
por: Wang, Quan, et al.
Publicado: (2013)

Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells
por: Zhang, Yafei, et al.
Publicado: (2012)

Synergistic effect of metformin on sorafenib in in vitro study using hepatocellular carcinoma cell lines
por: Chung, Yong-Gyu, et al.
Publicado: (2018)

Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma
por: Yoo, Jeong-Ju, et al.
Publicado: (2019)

Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism
por: Waraky, Ahmed, et al.
Publicado: (2014)

Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy
por: Li, Jun, et al.
Publicado: (2018)

Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation
por: Bort, Alicia, et al.
Publicado: (2017)

Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma
por: Yang, Xuran, et al.
Publicado: (2018)

Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways
por: Sun, Rong, et al.
Publicado: (2022)

Synergistic antitumor effects of tanshinone IIA and sorafenib or its derivative SC-1 in hepatocellular carcinoma cells
por: Chiu, Chien-Ming, et al.
Publicado: (2018)

Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib
por: Duan, Wendu, et al.
Publicado: (2018)

Acalculous Cholecystitis in a Patient with Hepatocellular Carcinoma on Sorafenib
por: Sanda, Mariko, et al.
Publicado: (2011)

HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation
por: Yuan, Jingsheng, et al.
Publicado: (2022)

Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature
por: Shinoda, Masahiro, et al.
Publicado: (2015)

Repurposing picropodophyllin as a potential thyroid eye disease treatment via delaying mitotic clonal expansion through a patient‐derived preclinical platform
por: Hu, Jing, et al.
Publicado: (2023)

FOXM1-Mediated LINC-ROR Regulates the Proliferation and Sensitivity to Sorafenib in Hepatocellular Carcinoma
por: Zhi, Yingru, et al.
Publicado: (2019)

Sorafenib Treatment and Modulation of the Sphingolipid Pathway Affect Proliferation and Viability of Hepatocellular Carcinoma In Vitro
por: Jakobi, Katja, et al.
Publicado: (2020)

OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53
por: Omar, Hany A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ku72e13o5flj74dbj91umumovk